Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

China · Delayed Price · Currency is CNY

39.59

+0.69 (1.77%)

Oct 14, 2026, 11:04 AM CST

Hangzhou Biotest Biotech Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	459.42	448.01	559.4	442.11	1,901	1,818
Revenue Growth	-7.29%	-19.91%	26.53%	-76.74%	4.57%	110.09%
Gross Profit	205.16	200.47	272.81	172.51	960.93	1,113
Operating Income	10.92	11.21	112.76	4.21	752.73	961
Net Income	20.3	49.25	169.52	106.61	773.63	833.59
Earnings Per Share	0.15	0.34	1.15	0.71	5.18	6.87
EPS Growth	-77.17%	-70.44%	61.00%	-86.21%	-24.64%	76.84%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Overseas	329.6
China	118.41
Total	448.01

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	1,265	1,489	1,698	1,917	2,040	1,729
Total Debt	100.11	0.49	0.44	3.04	7.64	12.47
Net Cash (Debt)	1,164	1,489	1,698	1,914	2,032	1,716
Net Cash Growth	-25.37%	-12.30%	-11.31%	-5.81%	18.43%	586.22%
Net Cash Per Share	8.85	10.28	11.52	12.83	13.60	14.15

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	67.59	106.47	128.83	131.38	703.21	908.12
Capital Expenditures	-140.9	-129.87	-245.05	-56.42	-178.92	-200.2
Free Cash Flow	-73.31	-23.4	-116.23	74.96	524.29	707.92
Free Cash Flow Growth	-	-	-	-85.70%	-25.94%	82.27%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	44.66%	44.75%	48.77%	39.02%	50.54%	61.20%
Operating Margin	2.38%	2.50%	20.16%	0.95%	39.59%	52.86%
Pretax Margin	2.94%	11.09%	34.84%	26.21%	47.44%	53.28%
Profit Margin	4.42%	10.99%	30.30%	24.11%	40.69%	45.85%
FCF Margin	-15.96%	-5.22%	-20.78%	16.95%	27.58%	38.94%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.700	0.700	1.071	0.571	1.571	2.143
Dividend Per Share Growth	-48.42%	-34.66%	87.50%	-63.64%	-26.67%	-
Dividend Yield	1.77%	1.89%	4.80%	2.88%	5.58%	5.24%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	252.03	112.24	20.36	30.29	6.37	8.94
P/FCF Ratio	-	-	-	43.08	9.40	10.53
PS Ratio	12.39	12.34	6.17	7.30	2.59	4.10